The single nucleotide polymorphism (SNP) **rs121913279** is located in the **BRCA1 gene**, which is a critical gene involved in DNA repair through homologous recombination. Variants in the BRCA1 gene, including rs121913279, are associated with an increased risk of hereditary breast and ovarian cancer syndrome (HBOC). Specifically, rs121913279 is a pathogenic variant that can significantly influence the clinical phenotype by impairing the gene's function, leading to genomic instability and a predisposition to cancer.

This variant is classified as pathogenic because it disrupts the normal function of the BRCA1 protein, which is essential for maintaining genomic integrity. Individuals carrying this variant are at a higher risk of developing breast cancer, ovarian cancer, and potentially other cancers, such as pancreatic cancer or prostate cancer, depending on the individual's sex and other genetic or environmental factors.

### Key Clinical Implications:
1. **Cancer Risk**: Carriers of rs121913279 have a significantly elevated lifetime risk of breast and ovarian cancer compared to the general population.
2. **Family History**: This variant is often found in families with a strong history of early-onset breast or ovarian cancer.
3. **Therapeutic Implications**: Patients with this variant may benefit from targeted therapies, such as PARP inhibitors, which exploit the defective DNA repair pathway in BRCA1-mutated cells.
4. **Preventive Measures**: Carriers may consider enhanced cancer screening, prophylactic surgeries (e.g., mastectomy or oophorectomy), or lifestyle modifications to reduce cancer risk.

---

**日本語での説明:**

一塩基多型（SNP）**rs121913279**は、DNA修復に重要な役割を果たす**BRCA1遺伝子**に位置しています。この遺伝子の変異（rs121913279を含む）は、遺伝性乳がん卵巣がん症候群（HBOC）のリスク増加と関連しています。特に、rs121913279は病原性変異として分類されており、BRCA1タンパク質の機能を損なうことで、ゲノムの不安定性を引き起こし、がんの発症リスクを高めます。

この変異は病原性とされており、BRCA1タンパク質の正常な機能を妨げるため、がんの発症に寄与します。この変異を持つ個人は、乳がん、卵巣がん、さらには膵臓がんや前立腺がん（性別や他の要因による）などのリスクが高まります。

### 主な臨床的影響:
1. **がんリスク**: rs121913279を持つキャリアは、一般集団と比較して乳がんや卵巣がんの生涯リスクが大幅に高くなります。
2. **家族歴**: この変異は、早期発症の乳がんや卵巣がんの家族歴を持つ家系でよく見られます。
3. **治療的影響**: この変異を持つ患者は、PARP阻害剤のような標的治療の恩恵を受ける可能性があります。これらの治療法は、BRCA1変異細胞の欠陥DNA修復経路を利用します。
4. **予防策**: キャリアは、がんスクリーニングの強化、予防的手術（例: 乳房切除術や卵巣摘出術）、または生活習慣の改善を検討することができます。

If you have further questions about this variant or its clinical implications, feel free to ask!  
この変異やその臨床的影響についてさらに質問があれば、お気軽にお尋ねください！